Vidya Sundareshan, MD
Infectious Disease · Springfield, ILNPI 1376790733
Payments from drug & device makers
What this record shows
This record is dominated by education: $283 of the $283 with a category attached, or 100.0%. 3 manufacturers reported payments, led by Insmed, Inc. at 47.8% of the total. Reporting peaked in 2020 at $135 and has fallen 70.4% since, to $40 in 2024.
Across 6 payments — averaging $47.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Insmed, Inc.$135
- Astellas Pharma US Inc$135
- Merck$13
Across 20 payments — averaging $5764.66 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Beigene, Ltd.$106K
- Pfizer$7K
- Merck$3K
What the payments were for
- Education$283100%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Insmed, Inc. | 2 | $135 |
| Astellas Pharma US Inc | 3 | $135 |
| Merck | 1 | $13 |
How this compares
$283 in reported general payments places this provider in the 55th percentile of 368 infectious disease providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 52 | $245,092 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 36 | $147,595 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 34 | $145,083 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 22 | $88,133 |
| DescovyEmtricitabine/Tenofov Alafenam | 22 | $50,409 |
| TivicayDolutegravir Sodium | 19 | $46,889 |
| Darunavir | 20 | $32,701 |
| EdurantRilpivirine Hcl | 14 | $21,941 |
| Daptomycin | 22 | $17,323 |
| Vancomycin Hcl | 81 | $10,257 |
| Cefepime Hcl | 50 | $8,048 |
| Ampicillin-SulbactamAmpicillin Sod/Sulbactam Sod | 25 | $5,402 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 16 | $4,982 |
| CeftriaxoneCeftriaxone Sodium | 54 | $4,178 |
| Yf-VaxYellow Fever Vaccine Live/Pf | 19 | $4,076 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Springfield
- Praveen MullangiSpringfield$7K
- Frank PalellaChicago$987K
- Jeffrey ShermanDeerfield$527K
- Catherine CreticosChicago$335K
- Babafemi TaiwoChicago$292K
- Beverly ShaChicago$202K
- Chad ZawitzChicago$193K
- Nancy GlickChicago$186K
- Kamaljit SinghChicago$138K
- Jorge ParadaMaywood$128K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.